Laurus Labs Q2 & H1 FY26 Earnings Results: Revenue Jump 33%, EBITDA Surges Over 130%

On October 23, 2025, Laurus Labs Ltd. (NSE: LAURUSLABS), a prominent R&D-focused pharmaceutical and biotech company in India, has released its financial results for Q2 and H1 FY26.

Laurus Labs Q2 & H1 FY26 Earnings Results Overview

Financial Performance

• Q2 FY26: Revenue ₹1,653 Cr (+35% YoY), EBITDA ₹429 Cr (+136%), EBITDA margin 26.0%, gross margin 59.9%. Net profit ₹195 Cr (+875%).
• H1 FY26: Revenue ₹3,223 Cr (+33%), EBITDA ₹818 Cr (+132%), EBITDA margin 25.4%, gross margin 59.6%. Net profit ₹358 Cr (+985%).
• EPS (Diluted) Q2 FY26: ₹3.6, H1 FY26: ₹6.6.

Key Highlights

• Strong growth driven by CDMO (Contract Development & Manufacturing Organisation) and Generics business.
• Gross margin improvement of 4.5–4.7% YoY due to favorable business mix and operational efficiency.
• Net debt reduced to 1.3x EBITDA despite continued CAPEX of ~15% of sales.
• Declared interim dividend of ₹0.80 per share.

Management Commentary

• Dr. Satyanarayana Chava, CEO: Laurus continues to lead in ARVs and expand CDMO programs. Strategic investments, like ₹16 Cr (US$2 mn) in Aarvik Therapeutics, strengthen ADC technology pipeline.
• V V Ravi Kumar, CFO: Revenue and EBITDA growth driven by Generics and CDMO. Operational leverage and improved business mix boosted margins. Focus remains on high-value CDMO/CMO opportunities for long-term shareholder returns.

About Laurus Labs

Laurus Labs is a research-driven pharmaceutical and biotech company focused on APIs and FDFs in ARV, oncology, cardiovascular, and gastro therapeutics. It offers end-to-end CDMO services, operates 15 global regulatory-approved facilities, and employs over 7,042 people, including 2,632+ scientists. Its sustainable “Smart & Green” chemistry approach ensures operational excellence.

Read More, Best Bank Stocks in November 2025: PNB, Axis Bank, HDFC Bank, and More Based on 5Y CAGR!

Laurus Labs Share Price Movement

Laurus Labs share price (NSE: LAURUSLABS) closed at ₹943.00 on October 23, 2025, up ₹19.10 or 2.07% from the previous session. The stock opened at ₹927.40, touched a high of ₹943.00 and a low of ₹920.70 during the day. The company has a market capitalisation of ₹50,500 crore and a P/E ratio of 99.99. Its 52-week high and low stand at ₹944.00 and ₹440.45, respectively. 

Conclusion

Laurus Labs delivered robust revenue and profit growth in H1 FY26, driven by CDMO and Generics. Strong margins, reduced debt, and strategic investments position the company well for long-term growth, while interim dividend rewards shareholders.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.